Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
Background: The identification of molecular and genetic markers to predict or monitor the
efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal …
efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal …
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
Purpose: There is substantial germline genetic variability within angiogenesis pathway
genes, thereby causing interindividual differences in angiogenic capacity and resistance to …
genes, thereby causing interindividual differences in angiogenic capacity and resistance to …
Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
Purpose The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical
outcome of mCRC patients receiving bev-containing regimens has been investigated in …
outcome of mCRC patients receiving bev-containing regimens has been investigated in …
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
Background FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and
efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises …
efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises …
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with …
TF Hansen, RP Christensen, RF Andersen… - International journal of …, 2012 - Springer
Purpose Bevacizumab and chemotherapy is a common choice for first-line treatment of
metastatic colorectal cancer (mCRC). So far, no predictive markers have been identified …
metastatic colorectal cancer (mCRC). So far, no predictive markers have been identified …
Upfront FOLFOXIRI+ bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
A Stein, D Atanackovic, B Hildebrandt, P Stübs… - British Journal of …, 2015 - nature.com
Background: The addition of bevacizumab (BEV) to standard doublet chemotherapy
improves outcomes compared with chemotherapy alone in patients with metastatic …
improves outcomes compared with chemotherapy alone in patients with metastatic …
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and …
V Formica, R Palmirotta, G Del Monte… - International journal of …, 2011 - Springer
Purpose The aim of this study is to evaluate the influence of germline vascular endothelial
growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody …
growth factor (VEGF) gene polymorphisms (VGPs) on the efficacy of the anti-VEGF antibody …
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
AJ Weickhardt, DS Williams, CK Lee, F Chionh… - British journal of …, 2015 - nature.com
Background: Bevacizumab prolongs progression-free survival (PFS) in patients with
metastatic colorectal cancer. We analysed the protein expression levels of vascular …
metastatic colorectal cancer. We analysed the protein expression levels of vascular …
VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Bevacizumab is used to treat metastatic colorectal cancer (mCRC). However, there are still
no available predictors of clinical outcomes. We investigated selected single nucleotide …
no available predictors of clinical outcomes. We investigated selected single nucleotide …